Jazz Pharmaceuticals to Present Xywav Narcolepsy Data at 2026 AAN Annual Meeting
New poster presentation will detail self-reported outcomes in patients with narcolepsy treated with high dosages of low-sodium oxybate in the DUET study.
New poster presentation will detail self-reported outcomes in patients with narcolepsy treated with high dosages of low-sodium oxybate in the DUET study.
Jazz reports second-quarter earnings, with growth driven in part by a 13% increase in Xywav sales.
Jazz Pharmaceuticals is challenging the FDA in district court over the FDA’s recent approval of a competing new narcolepsy drug, Lumryz.
The review evaluated all high-sodium oxybates, fixed-dose, and twice-nightly administrations in both oxybate-experienced patients and those who had not undergone prior treatment.
Read MoreDuring the second quarter, Jazz Pharmaceuticals registered a 39% year-over-year growth in net product sales of its low-sodium Xywav.
Read MoreSodium oxybate oral solution is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness in patients aged 7 and older with narcolepsy.
Read MoreA patient with type 2 narcolepsy reports an experience to her sleep physician that was not seen in any of the clinical trials.
Read MoreJazz Pharmaceuticals is presenting seven abstracts featuring new data from across its sleep medicine portfolio, encompassing idiopathic hypersomnia and narcolepsy.
Read MoreJazz Pharmaceutics says the benefits of reducing sodium intake resonate with prescribers as the large majority of new-to-oxybate narcolepsy patients continue to be prescribed Xywav.
Read MoreOn February 9, Jazz Pharmaceuticals plc made changes to its XYWAV and XYREM prescription forms to decrease prescriber confusion.
Read MoreNew clinical trial data shows that the medication Xywav significantly reduced the long sleep duration and excessive daytime sleepiness that are typical hallmarks of the sleep disorder idiopathic hypersomnia.
Read MoreJazz announced on Monday that the U.S. Food and Drug Administration granted them Orphan Drug Exclusivity for the medication Xywav for the treatment of idiopathic hypersomnia.
Read MoreThe FDA also published its summary of clinical superiority findings for Xywav for the treatment of cataplexy or excessive daytime sleepiness associated with narcolepsy.
Read MoreThirteen abstracts sponsored by Jazz Pharmaceuticals and five abstracts from investigator-sponsored trials will be presented at SLEEP 2021.
Read MoreThe AAN presentation further quantifies the previously reported Phase 3 top-line results.
Read MoreA literature review from Stanford University looks at how the popular narcolepsy medication sodium oxybate impacts heart health.
Read MoreResults of the double-blind, placebo-controlled, randomized-withdrawal, multicenter study were previously presented at World Sleep 2019.
Read More“There is significant need for greater awareness of idiopathic hypersomnia, which can severely impact a person’s daily life, and can often be misdiagnosed or undiagnosed over a substantial period of time.”
Read More